Carina Namih is a General Partner at Episode1 Ventures, a venture capital firm that invests in the top early-stage technology businesses in the UK.
The Episode1 team has backed some of UK’s biggest success stories such as Shazam, Natural Motion and CloudNC.
Carina joined Episode1 with a focus on investing in applied AI startups, where as a board director, she helps the founding teams build category-defining businesses.
Before joining Episode1, Carina was the co-founder and CEO of HelixNano, one of the first computational biology companies to successfully apply machine learning techniques to develop RNA vaccines. With a team from Harvard and backed by the likes of Y Combinator, the company is now adapting their synthetic biology capabilities to tackle COVID-19.
Carina also supports the wider UK ecosystem on the advisory board of the British Venture Capital Association.